Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)

Jiménez Vicente, Carlos; Esteve, Jordi; Baile González, Mónica; Pérez López, Estefanía; Martin Calvo, Carmen; Aparicio, Clara; Oiartzabal Ormategi, Itziar; Esquirol, Albert; Peña Muñoz, Felipe; Fernández Luis, Sara; Heras Fernando, Inmaculada; González Rodríguez, Ana Pilar; López García, Alberto; López Lorenzo, Jose Luis; Torrado, Tamara; Sáez Marín, Adolfo Jesús; Acosta Fleytas, Cynthia; García, Lucía; Villar, Sara; Filaferro, Silvia

Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)

This multicenter retrospective study by GETH-TC validates the prognostic value of the Allo-HCT Refined ELN 2022 risk classification in allografted AML patients. The new classification refines the ELN 2022 risk classification, dividing adverse-risk patients into two subgroups: Adv-Plus (AdvP), includ...

ver descrição completa

Detalhes bibliográficos
Autores:	Jiménez Vicente, Carlos, Esteve, Jordi, Baile González, Mónica, Pérez López, Estefanía, Martin Calvo, Carmen, Aparicio, Clara, Oiartzabal Ormategi, Itziar, Esquirol, Albert, Peña Muñoz, Felipe, Fernández Luis, Sara, Heras Fernando, Inmaculada, González Rodríguez, Ana Pilar, López García, Alberto, López Lorenzo, Jose Luis, Torrado, Tamara, Sáez Marín, Adolfo Jesús, Acosta Fleytas, Cynthia, García, Lucía, Villar, Sara, Filaferro, Silvia
Formato:	artículo
Fecha de publicación:	2025
País:	España
Recursos:	Universidad de Cantabria (UC)
Repositorio:	UCrea Repositorio Abierto de la Universidad de Cantabria
Idioma:	inglés
OAI Identifier:	oai:repositorio.unican.es:10902/36639
Acesso em linha:	https://hdl.handle.net/10902/36639
Access Level:	acceso abierto

id	ES_d281171d80bb86e4395634c7fe8f8d45
oai_identifier_str	oai:repositorio.unican.es:10902/36639
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)Jiménez Vicente, CarlosEsteve, JordiBaile González, MónicaPérez López, EstefaníaMartin Calvo, CarmenAparicio, ClaraOiartzabal Ormategi, ItziarEsquirol, AlbertPeña Muñoz, FelipeFernández Luis, SaraHeras Fernando, InmaculadaGonzález Rodríguez, Ana PilarLópez García, AlbertoLópez Lorenzo, Jose LuisTorrado, TamaraSáez Marín, Adolfo JesúsAcosta Fleytas, CynthiaGarcía, LucíaVillar, SaraFilaferro, SilviaThis multicenter retrospective study by GETH-TC validates the prognostic value of the Allo-HCT Refined ELN 2022 risk classification in allografted AML patients. The new classification refines the ELN 2022 risk classification, dividing adverse-risk patients into two subgroups: Adv-Plus (AdvP), including those with complex karyotype, MECOM (EVI1) rearrangement, or TP53 mutations/del(17p), and an additional adverse group (Adv). The study included 651 AML patients treated with at least one line of anthracycline-based induction therapy and in complete remission. According to the Allo-HCT Refined ELN 2022 risk classification, 19.4% (n = 126) patients were classified into the Favorable (Fav) risk, 38.1% (n = 248) into the Intermediate (Int) risk, 27.2% (n = 177) in the Adv and 15.4% (n = 100) in the AdvP. Outcomes were significantly poorer for patients allocated in the AdvP risk group (5-year OS rate: 32.3%, 5-year LFS rate: 24.3%, both p < 0.001 with the rest of subgroups) and a higher CIR (5-year CIR: 64.3%, p < 0.001). Patients in the Adv* risk group had similar outcomes than patients in the Int risk group (5-year OS rate: 70.2% vs. 66.7%, p = 0.69, 5-year LFS rate: 63.8% vs. 55.9%, p = 0.33). Multivariate analysis confirmed the dismal outcomes for AdvP patients for OS: Hazard Ratio (HR) = 3.05, and LFS: HR = 2.66, both p < 0.001. Our findings validate the Allo-HCT Refined ELN 2022 classification as a robust prognostic tool, particularly highlighting the poor outcomes for the AdvP subgroup.We thank our patients and the Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH-TC) for the support provided during the study development. In addition, Dr. Jordi Esteve and María Jesús Pascual Cascón for their mentorship and support during the study period. We additionally thank REDCap (Research Electronic Data Capture) service for permitting the use of their service without costs. REDCap is a secure, web-based software platform designed to support data capture for research studies.Nature Pub. GroupUniversidad de Cantabria20252025-01-01journal articlehttp://purl.org/coar/resource_type/c_6501NAhttp://purl.org/coar/version/c_be7fb7dd8ff6fe43info:eu-repo/semantics/articlehttps://hdl.handle.net/10902/36639Blood Cancer Journal, 2025, 15(1), 42reponame:UCrea Repositorio Abierto de la Universidad de Cantabriainstname:Universidad de Cantabria (UC)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:repositorio.unican.es:10902/366392026-06-02T12:39:31Z
dc.title.none.fl_str_mv	Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)
title	Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)
spellingShingle	Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC) Jiménez Vicente, Carlos
title_short	Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)
title_full	Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)
title_fullStr	Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)
title_full_unstemmed	Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)
title_sort	Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)
dc.creator.none.fl_str_mv	Jiménez Vicente, Carlos Esteve, Jordi Baile González, Mónica Pérez López, Estefanía Martin Calvo, Carmen Aparicio, Clara Oiartzabal Ormategi, Itziar Esquirol, Albert Peña Muñoz, Felipe Fernández Luis, Sara Heras Fernando, Inmaculada González Rodríguez, Ana Pilar López García, Alberto López Lorenzo, Jose Luis Torrado, Tamara Sáez Marín, Adolfo Jesús Acosta Fleytas, Cynthia García, Lucía Villar, Sara Filaferro, Silvia
author	Jiménez Vicente, Carlos
author_facet	Jiménez Vicente, Carlos Esteve, Jordi Baile González, Mónica Pérez López, Estefanía Martin Calvo, Carmen Aparicio, Clara Oiartzabal Ormategi, Itziar Esquirol, Albert Peña Muñoz, Felipe Fernández Luis, Sara Heras Fernando, Inmaculada González Rodríguez, Ana Pilar López García, Alberto López Lorenzo, Jose Luis Torrado, Tamara Sáez Marín, Adolfo Jesús Acosta Fleytas, Cynthia García, Lucía Villar, Sara Filaferro, Silvia
author_role	author
author2	Esteve, Jordi Baile González, Mónica Pérez López, Estefanía Martin Calvo, Carmen Aparicio, Clara Oiartzabal Ormategi, Itziar Esquirol, Albert Peña Muñoz, Felipe Fernández Luis, Sara Heras Fernando, Inmaculada González Rodríguez, Ana Pilar López García, Alberto López Lorenzo, Jose Luis Torrado, Tamara Sáez Marín, Adolfo Jesús Acosta Fleytas, Cynthia García, Lucía Villar, Sara Filaferro, Silvia
author2_role	author author author author author author author author author author author author author author author author author author author
dc.contributor.none.fl_str_mv	Universidad de Cantabria
description	This multicenter retrospective study by GETH-TC validates the prognostic value of the Allo-HCT Refined ELN 2022 risk classification in allografted AML patients. The new classification refines the ELN 2022 risk classification, dividing adverse-risk patients into two subgroups: Adv-Plus (AdvP), including those with complex karyotype, MECOM (EVI1) rearrangement, or TP53 mutations/del(17p), and an additional adverse group (Adv). The study included 651 AML patients treated with at least one line of anthracycline-based induction therapy and in complete remission. According to the Allo-HCT Refined ELN 2022 risk classification, 19.4% (n = 126) patients were classified into the Favorable (Fav) risk, 38.1% (n = 248) into the Intermediate (Int) risk, 27.2% (n = 177) in the Adv and 15.4% (n = 100) in the AdvP. Outcomes were significantly poorer for patients allocated in the AdvP risk group (5-year OS rate: 32.3%, 5-year LFS rate: 24.3%, both p < 0.001 with the rest of subgroups) and a higher CIR (5-year CIR: 64.3%, p < 0.001). Patients in the Adv* risk group had similar outcomes than patients in the Int risk group (5-year OS rate: 70.2% vs. 66.7%, p = 0.69, 5-year LFS rate: 63.8% vs. 55.9%, p = 0.33). Multivariate analysis confirmed the dismal outcomes for AdvP patients for OS: Hazard Ratio (HR) = 3.05, and LFS: HR = 2.66, both p < 0.001. Our findings validate the Allo-HCT Refined ELN 2022 classification as a robust prognostic tool, particularly highlighting the poor outcomes for the AdvP subgroup.
publishDate	2025
dc.date.none.fl_str_mv	2025 2025-01-01
dc.type.none.fl_str_mv	journal article http://purl.org/coar/resource_type/c_6501 NA http://purl.org/coar/version/c_be7fb7dd8ff6fe43
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/article
format	article
dc.identifier.none.fl_str_mv	https://hdl.handle.net/10902/36639
url	https://hdl.handle.net/10902/36639
dc.language.none.fl_str_mv	Inglés eng
language_invalid_str_mv	Inglés
language	eng
dc.rights.none.fl_str_mv	open access http://purl.org/coar/access_right/c_abf2 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	open access http://purl.org/coar/access_right/c_abf2 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv	openAccess
dc.publisher.none.fl_str_mv	Nature Pub. Group
publisher.none.fl_str_mv	Nature Pub. Group
dc.source.none.fl_str_mv	Blood Cancer Journal, 2025, 15(1), 42 reponame:UCrea Repositorio Abierto de la Universidad de Cantabria instname:Universidad de Cantabria (UC)
instname_str	Universidad de Cantabria (UC)
reponame_str	UCrea Repositorio Abierto de la Universidad de Cantabria
collection	UCrea Repositorio Abierto de la Universidad de Cantabria
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869420378632224768
score	15,811543

Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)

Registos relacionados